Inizio Ignite Sparks a New Era of Connected Advisory Solutions
January 7, 2026 | Inizio Ignite
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM to address the growing complexity of today’s pharmaceutical environment. Purpose-built and AI-enabled, Inizio Ignite helps clients shape strategy, drive scalable transformation, and deliver measurable impact uniting connected expertise and advanced technology platforms into a single advisory solution designed to deliver greater impact for clients and the patients they serve.
Inizio Ignite operates as part of Inizio’s broader global commercialization platform, enabling clients to seamlessly access deep, cross-functional expertise across the entire product lifecycle. With more than 10,500 experts in over 50 countries, Inizio brings together scientific, medical, commercial, analytics, and technology capabilities to help clients solve complex challenges in a flexible, client-centred way – from strategy through execution.
Focused exclusively on life sciences and healthcare, Inizio Ignite integrates Inizio’s former Advisory capabilities to create one of the largest and most specialized advisory partners in the sector. With more than 1,000 experts, including 100 PhD, PharmD, and MDs across more than 50 countries, Inizio Ignite advises clients across more than 20 therapy and disease areas and has partnered on 1,100 assets with all top 20 pharmaceutical companies. Across the product lifecycle, from early development through post-launch, Inizio Ignite supports data-driven portfolio and launch strategies, embeds advanced analytics, and translates insight into execution – delivering Intelligent Commercialization™ as part of Inizio’s end-to-end platform.
Remco op den Kelder, Global President of Inizio Ignite, said:
“By uniting our teams, we’re creating something new – an integrated partner bringing together the insight, strategy, and transformation support that pharma companies need to win in today’s market. This evolution represents a meaningful shift in how we serve our clients, delivering clearer answers, stronger guidance, and faster impact for the patients who rely on them.”
“With a seamlessly connected team, clients benefit from deeper expertise and broader capabilities at every stage of their journey. This transformation strengthens our ability to drive innovation at scale, pairing clarity and precision with the speed required to turn strategy into real-world impact. It positions us to advance the next generation of treatments and to help shape the future of human health.”
Find out more about Inizio Ignite and its solutions here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...
Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Pegasus expands Pharma team with senior hires
Five new recruits support further growth of the Pharma & Life Sciences team
Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU & Japan) 2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...
News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...
Emerging Markets: Your Essential Guide
Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges...
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,...